SB502

This bill establishes a mandatory due process framework for pharmaceutical wholesale distributors operating in Arkansas before they can limit or terminate the sale of controlled substances to pharmacies or other licensed providers. It requires distributors to provide annual education, conduct interviews regarding anti-diversion controls, and issue formal notice prior to restricting access to controlled substances. Wholesalers must provide a specific appeals process for customers and must notify the Arkansas State Board of Pharmacy during certain investigative processes. The bill mandates that any third-party compliance consultants utilized by wholesalers must be approved by the state board. Furthermore, it sets specific notice periods for potential violations and requires the board to impose a minimum $10,000 fine for violations of these procedural requirements. The bill includes an emergency clause to make these protections effective immediately upon signing.